Linagliptin N-Boc Impurity；Boc-Linagliptin；Linagliptin Impurities；Lingaliptin Intermediates
CAS: 668273-75-4
Chemical Formula:C30H36N8O4
Molecular Weight:572.66
Availability: R&D; Commercialization
⬤ CAS No.668273-75-4
⬤ Our Packaging type：
20kg barrel；5kg barrel；1kg bag；500g bag ; Customized Packaging
| Product Name | Tert-butyl((3s)-1-(7-(but-2-yn-1-yl)-3-Methyl-1-((4-Methylquinazolin-2-yl)Methyl)-2,6-dioxo-2,3,4,5,6,7-hexahydro-1h-purin-8-yl)piperidin-3-yl)carbaMate |
| CAS No. | 668273-75-4 |
| Chemical Formula | C30H36N8O4 |
| Molecular Weight | 572.66 |
| Related Categories | Lingaliptin Intermediates |
| Density | 1.32±0.1 g/cm3(Predicted) |
| Storage conditions | Refrigerator |
| Solubility | DMSO (slightly soluble, heated), methanol (slightly soluble, sonicated) |
| Acidity coefficient (pKa) | 12.13±0.20(Predicted) |
| Form | Solid |
| Color | Off-white to light yellow |
| Note | For synthetic research only: This product is specially designed and used for chemical synthesis research as an intermediate in drug development, organic synthesis and other chemical research fields. Not for human or clinical use |
| Drug development | Synthetic intermediates of Linagliptin；Drug Impurity Research |
| Chemical reagents and organic synthesis | Organic synthesis intermediates；Pharmaceutical intermediates research |
| Quality Control and Analysis | Drug purity testing；Stability studies（Study the impurities that may be produced during the storage or use of drugs and evaluate the stability and safety of drugs） |
Reliable Global Partner
“Tianming Pharmaceutical has redefined reliability for us. Their ability to deliver high-potency APIs and intermediates under tight deadlines—is unmatched. The team’s transparency in documentation and proactive updates make them a stress-free partner. A true backbone for our operations!”
March 18, 2024
Outstanding Technical Guidance
“Few suppliers align so perfectly with EU GMP requirements. Tianming’s commitment to audit-ready quality systems, batch traceability, and purity consistency has streamlined our production processes. Their diligence eliminates regulatory risks—a rare advantage in today’s market.”
February 15, 2024
Beyond Supplier, A Solutions Partner
“Tianming’s technical team doesn’t just deliver materials—they solve problems. When we faced stability challenges with a niche compound, their scientists proposed a tailored purity adjustment that saved our project timeline. Their agility transforms obstacles into opportunities.”
June 15, 2024
Strategic Growth Ally
“Over 5+ years, Tianming has consistently adapted to our evolving needs—whether scaling volumes or supporting custom synthesis projects. Their ethical pricing models and long-term vision make them more than a vendor; they’re integral to our competitive edge.”
April 27, 2024
Brigatinib manufacturer guide: Takeda (brand), Lonza (CDMO), and 72+ API vendors. Patent expiries: China 2026, US 2035. How to choose a reliable supplier for generic development.
This article summarizes 2025 latest research on ibrutinib’s long-term side effects, covering atrial fibrillation, bleeding, hypertension, infections and joint issues. It compares safety with newer BTK inhibitors and notes real-world treatment discontinuation risks.
Orforglipron vs retatrutide: oral small‑molecule GLP‑1 agonist vs triple‑hormone injectable. Phase 3 weight loss data, dosing schedules, side effects, regulatory status, and API manufacturing differences.
Leading provider of high-quality APIs and intermediates. Contact us for innovative solutions and expert support.
